不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas.
Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
EBV在宿主B细胞中长期处于休眠状态,超过90%的患者为无症状感染。然而,某些内源性因素(如免疫缺陷)或外源性因素(如HIV感染、炎症和缺氧)可破坏这一基础特性并导致疾病发展。EBV最初被发现与Burkitt淋巴瘤相关,目前从病因学上与B细胞、T细胞和NK细胞来源的恶性淋巴瘤相关。既往相关研究报道,EBV可促进淋巴瘤的发生和发展并影响预后。事实上,EBV相关淋巴瘤的发病机制涉及不同的病毒基因表达模式和复杂的细胞遗传学改变。本文总结了病毒的两个生命周期、潜伏模式、潜伏状态的建立及病毒再激活。我们还聚焦于EBV相关淋巴瘤的发生,并根据这些致病机制归纳并提出新的治疗视角或创新性解决方案。
Epstein-Barr virus (EBV) remains dormant in host B cells for a long time, and more than 90% of patients are asymptomatically infected.
However, some internal factors (such as immune deficiency) or exogenous factors (such as HIV infection, inflammation and hypoxia) can destroy this underlying property and lead to disease development. EBV was originally discovered in association with Burkitt lymphomas and is now etiologically associated with malignant lymphomas of B, T, and NK cell origins.
Previous relevant studies have reported that EBV could promote the occurrence and development of lymphomas and affect the prognosis. In fact, the pathogenesis of EBV-associated lymphomas involves different viral gene expression patterns and complex cytogenetic changes.
Here, the present study summarizes viral two life cycles, latent modes, the establishment of latency and viral reactivation.
We also focus on the occurrence of EBV-related lymphomas, generalize and put forward novel perspectives or innovative solutions for treatments according to these pathogenic mechanisms.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。